Transgene S.A.
OTC: TRGNF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alessandro Riva
- Employees
- 144
- Headquarters
- Illkirch-Graffenstaden, France
- IPO year
- 2021
- Market cap
- $122.6M
- Website
- https://www.transgene.fr
Loading TRGNF…
Loading profile data…Frequently asked questions about TRGNF
What does Transgene S.A. (TRGNF) do?
Transgene S.A. is a biotechnology company dedicated to the creation and advancement of therapeutic vaccines and oncolytic viruses. Its core mission is to develop innovative treatments for both cancer and various infectious diseases. The company's drug development pipeline includes several promising candidates: TG4050, a therapeutic vaccine, is c...
Where does TRGNF trade?
Transgene S.A. (TRGNF) trades on the Other OTC.
What sector is TRGNF in?
Transgene S.A. (TRGNF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Transgene S.A.?
Alessandro Riva is the chief executive officer of Transgene S.A. (TRGNF).
Where is Transgene S.A. headquartered?
Transgene S.A. is headquartered in France.
Does TRGNF pay a dividend?
Transgene S.A. (TRGNF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TRGNF go public?
Transgene S.A. (TRGNF) completed its initial public offering in 2021.